Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression

Australian and New Zealand Journal of Psychiatry

Volumn 42, Issue 4, 2008, Pages 346-349

  Malhi, Gin S ^a,b,c   Ng, Felicity ^d   Berk, Michael ^d,e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Clinical Assessment Diagnostic Evaluation Australia   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Combination antidepressants; Mirtazepine; Resistant depression; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; MIRTAZAPINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; AGED; ARTICLE; CASE STUDY; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; PROSPECTIVE STUDY; REMISSION; SEDATION; SEROTONIN SYNDROME; SIDE EFFECT; STATISTICS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COHORT STUDIES; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 40749139070     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670701881587     Document Type: Article

References (19)

1. Parker, G. and Crawford, J. (2007) Judged effectiveness of differing antidepressant strategies by those with clinical depression. Aust N Z J Psychiatry, 41, pp. 32-37.
2. Trivedi, MH and Kleiber, BA. (2001) Algorithm for the treatment of chronic depression. J Clin Psychiatry, 62, pp. 22-29.
3. de la Gandara, J., Aguera, L., Rojo, JE, Ros, S. and de Pedro, JM. (2005) Use of antidepressant combinations: Which, when and why? Results of a Spanish survey. Acta Psychiatr Scand Suppl, 428, pp. 32-26.
4. Dodd, S., Horgan, D., Malhi, GS and Berk, M. (2005) To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord, 89, pp. 1-11.
5. Ng, F., Dodd, S. and Berk, M. (2006) Combination pharmacotherapy in unipolar depression. Expert Rev Neurother, 6, pp. 1049-1060.
6. Rojo, JE, Ros, S., Aguera, L., de la Gandara, J. and de Pedro, JM. (2005) Combined antidepressants: Clinical experience. Acta Psychiatr Scand Suppl, 36:428, pp. 25-31.
7. Horgan, D., Dodd, S. and Berk, M. (2007) A survey of combination antidepressant use in Australia. Australas Psychiatry, 15, pp. 26-29.
8. Stahl, SM. (2000) Essential psychopharmacology: Neuroscientific basis and practical applications, Cambridge University Press, Cambridge
9. Roughead, EE, McDermott, B. and Gilbert, AL. (2007) Antidepressants: prevalence of duplicate therapy and avoidable drug interactions in Australian veterans. Aust N Z J Psychiatry, 41, pp. 366-370.
10. Stahl, SM. (1998) Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. J Clin Psychiatry, 59, pp. 5-14.
11. Thase, ME. (2002) What role do atypical antipsychotic drugs have in treatment-resistant depression?. J Clin Psychiatry, 63, pp. 95-103.
12. Machado, M., Iskedjian, M., Ruiz, I. and Einarson, TR. (2006) Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin, 22, pp. 1825-1837.
13. Yurgelun-Todd, DA, Gruber, SA, Kanayama, G., Killgore, WD, Baird, AA and Young, AD. (2000) fMRI during affect discrimination in bipolar affective disorder. Bipolar Disord, 2, pp. 237-248.
14. Hannan, N., Hamzah, Z., Akinpeloye, HO and Meagher, D. (2007) Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness. J Psychopharmacol, 21, pp. 161-164.
15. McGrath, PJ, Stewart, JW and Fava, M. (2006) Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: A STAR*D report. Am J Psychiatry, 163, pp. 1531-1541 1666.
16. Ruhe, HG, Huyser, J., Swinkels, JA and Schene, AH. (2006) Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: Systematic review. Br J Psychiatry, 189, pp. 309-316.
17. Rush, AJ, Trivedi, MH and Wisniewski, SR (2006) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med, 354, pp. 1231-1242.
18. Trivedi, MH, Fava, M. and Wisniewski, SR (2006) Medication augmentation after the failure of SSRIs for depression. N Engl J Med, 354, pp. 1243-1252.
19. Trivedi, MH, Rush, AJ and Wisniewski, SR (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry, 163, pp. 28-40.